Vericel (NASDAQ:VCEL) Shares Gap Down - Time to Sell?

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Vericel Corporation (NASDAQ:VCEL - Get Free Report)'s stock price gapped down before the market opened on Thursday . The stock had previously closed at $40.66, but opened at $36.98. Vericel shares last traded at $37.74, with a volume of 306,297 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts recently commented on VCEL shares. Wall Street Zen lowered shares of Vericel from a "hold" rating to a "sell" rating in a report on Monday, May 12th. Stephens reiterated an "overweight" rating and set a $67.00 price target on shares of Vericel in a report on Monday, June 16th. Canaccord Genuity Group lowered their price target on shares of Vericel from $61.00 to $58.00 and set a "buy" rating for the company in a report on Friday. Finally, Truist Financial decreased their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a report on Friday, April 11th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Vericel has an average rating of "Moderate Buy" and a consensus price target of $59.86.

Vericel Trading Up 1.0%

The firm has a market capitalization of $1.82 billion, a P/E ratio of 297.92 and a beta of 1.27. The company's fifty day simple moving average is $40.83 and its 200 day simple moving average is $45.40.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.03. The business had revenue of $63.24 million during the quarter, compared to analyst estimates of $64.61 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The company's revenue for the quarter was up 20.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.10) EPS. On average, analysts predict that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of Vericel

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Captrust Financial Advisors grew its position in shares of Vericel by 3.4% in the 4th quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company's stock worth $336,000 after buying an additional 199 shares during the period. State of Wyoming grew its position in shares of Vericel by 3.8% in the 1st quarter. State of Wyoming now owns 10,428 shares of the biotechnology company's stock worth $465,000 after buying an additional 381 shares during the period. Summit Investment Advisors Inc. grew its position in shares of Vericel by 8.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,137 shares of the biotechnology company's stock worth $282,000 after buying an additional 405 shares during the period. Maryland State Retirement & Pension System grew its position in shares of Vericel by 2.8% in the 2nd quarter. Maryland State Retirement & Pension System now owns 14,795 shares of the biotechnology company's stock worth $630,000 after buying an additional 408 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its position in shares of Vericel by 2.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 20,092 shares of the biotechnology company's stock worth $855,000 after buying an additional 516 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.